Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | EDNRB | P24530 | 2/20 | 0.33 |
| ▸ | EDNRA | P25101 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683 | 0.88 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1921 | 0.88 | BRD4 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1606639 | 0.82 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1652 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1173 | 0.76 | CYP1A2 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL18597726 | 0.76 | POLB (0.51) | BRD4EDNRBEDNRAALDH1A1NPC1 | |
| SCHEMBL1185 | 0.74 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL14789795 | 0.74 | ALDH1A1 (0.39) | TRPV1FFAR4ALDH1A1NPC1RAB9A | |
| SCHEMBL18597812 | 0.74 | CYP1A2 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL1279 | 0.74 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20140256744-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2483269-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2483253-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8217066-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082181-A1 | Compounds as Lysophosphatidic Acid Receptor Antagonists | Amira Phamaceuticals, Inc. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041729-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256744-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | CYP1A2 4291/4885CYP3A4 4639/4885CYP2C9 4650/4885 |
| US-20110082164-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | CYP1A2 4291/4885CYP3A4 4639/4885CYP2C9 4650/4885 |
| US-20110082181-A1 | Compounds as Lysophosphatidic Acid Receptor Antagonists | LPAR1, LPAR2, LPAR4 | CYP1A2 4342/4885CYP3A4 4616/4885CYP2C9 4732/4885 |
| US-10000456-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | LPAR1, LPAR2, LPAR4 | CYP1A2 4291/4885CYP3A4 4639/4885CYP2C9 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.